Author: Lichao Fan; Chang Liu; Na Li; Huan Liu; Ye Gu; Yongyu Liu; Yu Chen
Title: Medical treatment of 55 patients with COVID-19 from seven cities in northeast China who fully recovered: a single-center, retrospective, observational study Document date: 2020_3_30
ID: hc0za6fh_21
Snippet: is the (which was not peer-reviewed) The copyright holder for this preprint . https://doi.org/10.1101/2020.03.28.20045955 doi: medRxiv preprint and alpha-interferon. 2 In the present study, 53 patients (96·36%) received antiviral therapy early in the course of their disease for a median time of 14 days (IQR 12-18 days). In the mild group, 17 ( 37·78%) of the patients were treated with umifenovir and another 17 (37·78%) received a combination o.....
Document: is the (which was not peer-reviewed) The copyright holder for this preprint . https://doi.org/10.1101/2020.03.28.20045955 doi: medRxiv preprint and alpha-interferon. 2 In the present study, 53 patients (96·36%) received antiviral therapy early in the course of their disease for a median time of 14 days (IQR 12-18 days). In the mild group, 17 ( 37·78%) of the patients were treated with umifenovir and another 17 (37·78%) received a combination of umifenovir + lopinavir/ritonavir for a median time of 14 days (IQR 12-17 days).
Search related documents:
Co phrase search for related documents- alpha interferon and disease course: 1, 2, 3, 4
- alpha interferon and lopinavir umifenovir ritonavir combination: 1
- alpha interferon and median time: 1, 2
- alpha interferon and mild group: 1, 2, 3, 4
- alpha interferon and present study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
- antiviral therapy and disease course: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- antiviral therapy and median time: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- antiviral therapy and mild group: 1, 2, 3, 4, 5, 6, 7, 8
- antiviral therapy and present study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- antiviral therapy and umifenovir treat: 1
- disease course and median time: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- disease course and mild group: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
- disease course and present study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- median time and mild group: 1, 2, 3, 4, 5, 6, 7, 8, 9
- median time and present study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- median time and umifenovir treat: 1
- mild group and present study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
Co phrase search for related documents, hyperlinks ordered by date